Citations

Clear

60 citation(s) found for "Scherber, Robyn".

The Impact of Medical Comorbidities in MPN-Related Fatigue
Scherber, Robyn M. , Senyak, Zhenya, Clark, Matthew , Boxer, Michael , McCallister, Archie, Cotter, Mary, VanHusen, Barbara, Harrison, Claire , Dueck, Amylou C. , Mesa, Ruben A.

Mayo Clinic

Blood | October 10, 2019 | Volume: 124 | Issue: 21 | Pages: 1862-1862

10.1182/blood.v124.21.1862.1862 Get It

Abstract Background: Philadelphia chromosome negative myeloproliferative neoplasms (MPN) include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Pertinent to these disorders is the high persistence, prevalence, and severity of fatigue. Overall, excessive fatigue compared to age and gender matched controls occurs in greater than 95% of MPN patients (Blood. 2011;118(2):401-8). Physiologic etiologies of fatigue in these patients include cytokine dysregulation and impaired hematopoiesis, however to date no one has investigated the impact that cofounding medical illnesses have on MPN fatigue burden. Methods: A 70-item internet-based survey was developed by a team of MPN investigators, patient advocates from MPN Forum, and hosted by the Mayo Clinic Survey Research Center. The survey was promoted online via multiple MPN-related webpages including the MPN Forum, MPN Net, MPN Research Foundation, and MPN Voice during late February to March of 2014. Surveyed data included disease demographics such as splenomegaly, thrombosis, hemorrhage transfusions, medications, and phlebotomies. The MPN-SAF (including the MPN 10) was utilized including the 10-item brief fatigue inventory was used to assess disease burden (Blood. 2011 Jul 14;118(2):401-8). Comorbid conditions were assessed, including hypothyroidism, anemias, sleep disturbances, obesity, and heart and lung disorders. Data: Demographics. Overall 1788 MPN patients participated in the survey. Of these, 1676 consented to participate and provided additional data (i.e., completed at least 10 questions). Of these, 555 (33%) patients had ET, 651 (39.0%) had PV, and 417 (25.0%) had MF. Among MF patients, 44.1% had primary MF, 29.7% had post-PV MF, and 26.2% had post-ET MF. Respondents were 68% female with a mean age of 59. Overall brief fatigue inventory score had a mean of 4.4 (range 0-10). MPN-10 score average was 28.4 (range 0-83). Medical Comorbidities. Overall, many patients endorsed having comorbid medical diseases that could contribute to overall fatigue (Table1). Overall 20.2% of patients endorsed having low thyroid function, with 10% indicating they obtained this diagnosis in the last six months. Twenty three percent endorsed having a new sleep disturbance in the last six months. On average, patients tended to have an average to above average BMI (mean =26.3, median = 25.0). However, many patients also experienced a high rate of unintended weight loss (11.8% with >11lb weight loss in the last 6 months). Cytopenias were also frequently encountered, with 14.7% of participants having required previous transfusions. Among these, 46% required transfusions in the last 6 months. Thrombosis (18.3%), hemorrhage (14.7%), and anemia (48.0%) were relatively common. In the last six months, 11.1% of patients required iron supplementation and 2.2% required erythropoietin injections. Many patients also endorsed the use of medications that could contribute to overall fatigue. Correlations. Items significantly correlated with worsened fatigue score (BFI greater than or equal to four) included female gender (<0.001), age (p=0.0047), lower education level (<0.001) and lower BMI (<0.001). Current use of alcohol and tobacco was also significantly associated with greater burden of fatigue (<0.001 and 0.0025, respectively). Items not significantly associated with fatigue included DIPSS (MF only), IPSET (ET only) or PV risk scoring. Conclusions Overall patients with MPN experience an exclusive pattern of disabling fatigue. Many fatigue-related medications and medical comorbidities may contribute to the debilitating fatigue seen among MPN patients, although no specific comorbidities could account for the high prevalence of fatigue. Rates of comorbid disease burden varied widely compared to the general population. For some diseases including diabetes, rates among MPN populations were less than the general population (National Diabetes Statistics Report, 2014), however the rates of other comorbidities, such as hypothyroidism, were higher (J Clin Endocrinol Metab 2002;87:489–99). Similar to our previous studies, females tended to suffer from a higher mean fatigue burden than males (Geyer ASH 2014). Clinical and research-related determination of fatigue should take into account cofounding comorbid medical conditions that can contribute to overall fatigue burden. Disclosures Harrison: Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau; Sanofi: Honoraria, Speakers Bureau; Shire: Speakers Bureau; CTI: Consultancy; YM Bioscience: Consultancy; Gilead: Consultancy; SBio: Consultancy. Mesa:Incyte: Research Funding; Novartis: Consultancy; Gilead: Research Funding; Genentech: Research Funding; Promedior: Research Funding; Ns Pharma: Research Funding; Celgene: Research Funding; Lilly: Research Funding; Cti: Research Funding.
Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients
Geyer, Holly L. , Scherber, Robyn M. , Xiao, Zhijian , Slot, Stephanie, Fuentes, Ana Kerguelen, Döhner, Konstanze , Harrison, Claire , Radia, Deepti , Muxí, Pablo , Sackman, Federico, Besses, Carlos , Cervantes, Francisco , Johansson, Peter , Andréasson, Björn , Rambaldi, Alessandro , Barbui, Tiziano , Samuelsson, Jan , Birgegård, Gunnar , Bonatz, Karin, Reiter, Andreas , Boyer, Françoise, Étienne, Gabriel , Ranta, Dana, Roy, Lydia , Cahn, Jean‐Yves , Maldonado, Norman I, Ferrari, Maria Luisa, Cannon, Keith, Boekhorst, Peter A.W. te , Schouten, Harry C. , Pahl, Heike L. , Stegelmann, Frank , Xu, Junqing , Zhang, Peihong , Rambaldi, Alessandro , Dueck, Amylou C. , Kiladjian, Jean‐Jacques , Zweegman, Sonja , Hernández‐Maraver, Dolores , Vannucchi, Alessandro M. , Passamonti, Francesco , Ianotto, Jean‐Christophe , Barosi, Giovanni , Grießhammer, Martin , Lehmann, Thomas , Xu, Zefeng , Zhang, Yue , Sun, Xiujuan , Mesa, Ruben A.

Mayo Clinic

Blood | October 9, 2019 | Volume: 124 | Issue: 21 | Pages: 1848-1848

10.1182/blood.v124.21.1848.1848 Get It

Abstract Background Polycythemia vera (PV) is a clonal myeloproliferative disorder characterized by erythrocytosis, splenomegaly and a frequently burdensome symptom profile. Despite current guidelines of aspirin, phlebotomy, and selective cytoreduction, many patients have inadequately controlled PV-related symptoms and/or disease features. We performed a comparison of PV symptom burden/disease feature phenotypes to understand unmet needs in current medical management. Methods Data was collected prospectively amongst an international cohort of PV patients including symptom burden, demographics, and disease features. Subgroups were identified who had previously failed hydroxyurea (PV-HU), required ongoing phlebotomy (PV-P), had palpable splenomegaly (PV-S), or had all 3 features (PV-HUPS). Control groups were derived from the remaining PV patients lacking the specified subgroup trait; patients in whom the trait status was unknown were excluded from each respective control group. All participants completed the MPN specific symptom burden questionnaire (MPN-SAF TSS (MPN-10 – Table 1)) and had no prior history of splenectomy. Surveyed symptoms on the MPN-10 included the patient's perceptions of common MPN-related symptoms and overall quality of life (QOL) on a 0 (absent) to 10 (worst imaginable) scale. PV risk scores were calculated using the 2013 criteria (Leukemia 2013). Comparison of symptoms between groups employed t-tests. Results Patient Demographics and Disease Features Between Phenotypic Groups A total of 1334 PV patients completed the MPN-10, and were assigned to categories of PV-HU (499 [37%]), PV-P (646 [48%]), PV-S (369, [28%]), and PV-HUPS (148 [12%]). The demographics between these groups were similar (comparable age (median range 60-63), PV risk scores (mean risk range: Low 16.4-23.7%; Intermediate 31.4%-36.6%; High 42.8%-47%). Mean hemoglobin was similar among PV subgroups (range 14.4-14.9); PV-HUPS had a higher mean WBC count (20.3 g/dL vs. 8.8-11.8 g/dL) and platelet count (703.5 x 10(9)/L vs. 327.5-462.8 x 10(9)/L), and disease duration (11.5 years vs. 6.4-8.8 years). Prior thrombosis was most common in PV-S patients (28.5% vs. 21.8-25.2%) and prior hemorrhage was most common in PV-HUPS patients (23.8% vs. 13.7-15.8%). Symptom Burden The MPN-10 scores of each problematic PV phenotype (HU, P, S, HUPS) were compared to the remainder of the PV cohort lacking the trait (PV-control; Table 1). Both individual symptom scores and TSS were highest for PV-HUPS patients (mean TSS 32.5 vs. 27.7-29.2). All problematic PV subgroups demonstrated significant differences for individual symptoms and TSS compared to PV-control. Comparing "problematic" subgroup responses, PV-HU patients described more inactivity whereas PV-S patients described more early satiety and pruritus. No statistical differences were noted in PV-HU, PV-P and PV-HUPS patient responses to MPN-10 items of "fever" and "weight loss". Discussion PV patients who have either failed HU, are undergoing phlebotomy and/or have splenomegaly exhibit moderate to severe symptomatology and demonstrate unmet medical need for management. As evidenced in this study, considerable overlap in symptomatology exists in PV-HU, PV-P, PV-S and PV-HUPS. Current randomized trials of JAK inhibitors have demonstrated benefits in a PV-HUPS phenotype. This data suggests that PV patients with any evidence of inadequate control (PV-HU, P, or S) have similarly unmet needs and may be candidates for clinical trials, intensification of medical therapy or perhaps JAK inhibitor therapy. Disclosures Kiladjian: Shire Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees. Zweegman:Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Millennium: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees, Research Funding. Besses:Shire Pharmaceuticals: honoraria for educational lectures Other. Birgegard:Shire Pharmaceuticals: Consultancy, Honoraria, Research Funding. Etienne:Novartis, BMS, Pfizer, Ariad: Honoraria. Roy:Merck: Peg-Interferon provided for academic clinical trial in CML Other. te Boekhorst:Novartis: Consultancy. Griesshammer:Novartis: Honoraria; Shire: Honoraria; Sanofi: Honoraria; Amgen: Honoraria; Roche: Honoraria. Mesa:Incyte Corporation, CTI, NPS Pharma, Inc., Gilead Science Inc., Celgene: Research Funding.
Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies
Mazza, Gina L. , Langlais, Blake, DeWees, T.A. , Geyer, Holly L. , Scherber, Robyn M. , Dueck, Amylou C. , Kunze, Katie L. , Langlais, Blake T., DeWees, Todd A, Dueck, A. C. , DeWees, Todd A , Mazza, Gina L , Kosiorek, Heidi , Mesa, Ruben A.

Mayo Clinic

Leukemia & Lymphoma | January 17, 2019 | Volume: 60 | Issue: 7 | Pages: 1789-1795

10.1080/10428194.2018.1548705 | PMID 30652523 Get It

Symptom assessment in patients with JAK inhibitor naïve and JAK inhibitor failed myelofibrosis.
Su, Yun , Woolfson, Adrian , Turnbull, Kathleen, Harrison, Claire , Scherber, Robyn M. , Shields, A. F., Krohe, Meaghan , Ojo, Funke, Pompilus, Farrah , Prchal, Josef T. , Jabbour, Elias , Shields, Alan, Mesa, Ruben A.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e18559-e18559

10.1200/jco.2016.34.15_suppl.e18559 Get It

Creation and validation of the “myMPN” prospective patient registry of myeloproliferative neoplasm patients.
Scherber, Robyn M. , Whyte, Lindsey, Woehrle, Michelle, Harrison, Claire , Dueck, Amylou C. , Verstovšek, Srđan , Mesa, Ruben A.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e19031-e19031

10.1200/jco.2018.36.15_suppl.e19031 Get It

Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life?
Langlais, Blake, Geyer, Holly L. , Scherber, Robyn M. , Dueck, Amylou C. , Langlais, Blake T., Geyer, Holly, Dueck, A. C. , Mesa, Ruben A.

Mayo Clinic

Leukemia & Lymphoma | July 23, 2018 | Volume: 60 | Issue: 2 | Pages: 402-408

10.1080/10428194.2018.1480768 | PMID 30033837 Get It

How we diagnose and treat systemic mastocytosis in adults
Scherber, Robyn M. , Borate, Uma

Mayo Clinic

British Journal of Haematology | October 19, 2017 | Volume: 180 | Issue: 1 | Pages: 11-23

10.1111/bjh.14967 | PMID 29048112 Get It

Summary Rapid advances in the understanding of the molecular biology, data from translational and clinical trials, and retrospective analyses has influenced the diagnosis and treatment of systemic mastocytosis ( SM ). Many options have existed for the symptomatic management of SM patients, but recent evolution in regards to the molecular underpinnings of this disease and our ability to distinguish clonal mastocytosis from mast cell activation syndrome has changed our treatment paradigm and opened new opportunities for understanding genetic risk, transformation to mast cell leukaemia, and treatment choices. Key to this change has been the discovery of the KIT mutation and the use of next generation sequencing to evaluate for co‐existing molecular mutations that may define the disease course. Careful diagnosis, judicious symptom management and close surveillance of those who may have yet undiagnosed disease is paramount in providing optimal management. In this article, we review the diagnosis and provide a paradigm for the management of SM patients.
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Harrison, Claire , Mead, Adam J. , Panchal, Anesh, Fox, Sonia, Yap, Christina , Gbandi, Emmanouela, Houlton, Aimee E., Alimam, Samah , Ewing, Joanne, Wood, Marion , Chen, Frederick , Coppell, Jason, Panoskaltsis, Nicki , Knapper, Steven , Ali, Sahra, Hamblin, Angela , Scherber, Robyn M. , Dueck, Amylou C. , Jackson, Aimee , Scherber, Robyn, Mesa, Ruben, Dueck, A. C. , Mead, Adam J , Cross, Nicholas C.P. , Mesa, Ruben A. , McMullin, Mary Frances , Knapper, Steven , Yap, Christina

Mayo Clinic

Blood | August 9, 2017 | Volume: 130 | Issue: 17 | Pages: 1889-1897

10.1182/blood-2017-05-785790 | PMID 29074595 Get It

Key Points After hydroxycarbamide therapy in high-risk ET, ruxolitinib showed no improvement for complete or partial response rates compared with BAT. Ruxolitinib significantly improved some disease-related symptoms, but rates of thrombosis, hemorrhage, or transformation were not different.
The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts
Scherber, Robyn M. , Geyer, Holly L. , Dueck, Amylou C. , Cavazzina, Riccardo, Masciulli, Arianna, Scarano, Marco, Barbui, Tiziano , Scherber, Robyn Marie, Geyer, Holly Lynn, Dueck, A. C. , Kosiorek, Heidi , Finazzi, Guido , Vannucchi, Alessandro M. , Mesa, Ruben A.

Mayo Clinic

Leukemia & Lymphoma | November 10, 2016 | Volume: 58 | Issue: 6 | Pages: 1481-1487

10.1080/10428194.2016.1246733 | PMID 27830999 Get It

Evaluating Elevated Hemoglobin—Reply
Scherber, Robyn M. , Mesa, Ruben A.

Mayo Clinic

JAMA | September 13, 2016 | Volume: 316 | Issue: 10 | Pages: 1115

10.1001/jama.2016.11335 | PMID 27623473 Get It